Docoh
Loading...

INCY Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Company profile

Ticker
INCY
Exchange
Website
CEO
Herve Hoppenot
Employees
Incorporated
Location
Fiscal year end
Former names
INCYTE GENOMICS INC, INCYTE INC, INCYTE PHARMACEUTICALS INC
SEC CIK
IRS number
943136539

INCY stock data

(
)

Press releases

Pro users get this 30m faster
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
8 Apr 21
INDIANAPOLIS, April 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care
Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
6 Apr 21
INDIANAPOLIS, April 6, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the
Incyte Announces the European Commission Approval of Pemazyre® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement
29 Mar 21
- Pemazyre is the first targeted therapy approved in the EU for this indication Incyte (NASDAQ:INCY) today announced that the European Commission (EC) has approved Pemazyre® (pemigatinib) for the treatment of
Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy
23 Mar 21
Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation
18 Mar 21

Calendar

9 Feb 21
11 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Incyte earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1.51B 1.51B 1.51B 1.51B 1.51B 1.51B
Cash burn (monthly) (positive/no burn) 26.58M (positive/no burn) 21.97M (positive/no burn) 10.38M
Cash used (since last report) n/a 90.17M n/a 74.55M n/a 35.23M
Cash remaining n/a 1.42B n/a 1.44B n/a 1.48B
Runway (months of cash) n/a 53.6 n/a 65.5 n/a 142.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Apr 21 Dhanak Dashyant Common Stock Sell Dispose S No Yes 81.57 396 32.3K 27,336
31 Mar 21 Baker Bros. Advisors Common Stock Grant Aquire A Yes No 0 364 0 29,314,516
31 Mar 21 Baker Bros. Advisors Common Stock Grant Aquire A Yes No 0 364 0 2,850,749
31 Mar 21 Clancy Paul J Common Stock Grant Aquire A No Yes 81.27 298 24.22K 5,094
31 Mar 21 Dixon Wendy L Common Stock Grant Aquire A No Yes 81.27 225 18.29K 14,878
31 Mar 21 Harrigan Edmund Common Stock Grant Aquire A No Yes 81.27 219 17.8K 2,711

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

92.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 486 484 +0.4%
Opened positions 67 64 +4.7%
Closed positions 65 60 +8.3%
Increased positions 177 173 +2.3%
Reduced positions 164 178 -7.9%
13F shares
Current Prev Q Change
Total value 19.83B 17.93B +10.6%
Total shares 202.54M 199.86M +1.3%
Total puts 731.8K 692.6K +5.7%
Total calls 598.3K 798.8K -25.1%
Total put/call ratio 1.2 0.9 +41.1%
Largest owners
Shares Value Change
TROW T. Rowe Price 32.59M $2.84B +5.4%
Baker Bros. Advisors 32M $2.78B +0.0%
Vanguard 20.16M $1.75B -1.6%
BLK Blackrock 17.81M $1.55B +4.4%
Wellington Management 13.5M $1.17B -4.4%
STT State Street 8.69M $755.78M -0.4%
Capital International Investors 6.79M $590.58M -8.1%
Renaissance Technologies 5.89M $512.24M -5.1%
Geode Capital Management 3.25M $282.39M +1.3%
Dodge & Cox 3.25M $282.91M -1.1%
Largest transactions
Shares Bought/sold Change
Norges Bank 1.88M +1.88M NEW
TROW T. Rowe Price 32.59M +1.68M +5.4%
IVZ Invesco 1.04M -1.62M -61.1%
ARK Investment Management 1.78M +1.2M +207.7%
GS Goldman Sachs 513.29K -788.5K -60.6%
BLK Blackrock 17.81M +753.01K +4.4%
Polar Capital 636.01K +636.01K NEW
Wellington Management 13.5M -616.88K -4.4%
Capital International Investors 6.79M -600.31K -8.1%
POLR Polar Capital 0 -585.93K EXIT
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: adaptive, AEs, aggressive, aid, AIHA, Allergy, ancestry, appetite, arm, ascertain, ASCT, ASH, baccalaureate, BAT, benchmarking, bendamustine, binary, BIRC, Black, Blinded, BOR, BRAVE, broaden, Brown, budgetary, Canada, Canadian, canal, carefully, caution, CCA, CCPA, Cohort, color, compliant, compromise, confidence, constrain, constrained, context, conventional, cracked, creative, creed, culture, Defense, developmental, dialogue, dictated, discriminate, dMMR, DOR, economy, EHS, emerge, emergency, England, enrichment, enterprise, epidemic, equitably, ESMO, Estate, EUA, excellence, ExpirationIncluding, extracorporeal, fashion, febrile, firstMIND, FOP, freely, frontMIND, gender, geography, goal, graduate, Hall, harassment, home, HS, hybrid, IAI, Ib, ill, impede, inclusion, inclusive, infection, inMIND, Internet, invasive, job, Jopwell, Journal, Katherine, Labour, lenalidomide, lifeblood, lymph, marital, MCC, mDOR, median, membrane, mental, mentoring, microsatellite, military, mismatch, MONJUVI, Montreal, mortality, Motion, movement, myeloma, na, nausea, negligible, NIAID, Nimble, nonrefundable, North, numerical, orientation, outbreak, outset, outsourced, oxygen, oxygenation, pandemic, participatory, partnership, pathogenic, payroll, pemazyre, peptide, petitioner, philosophy, plamotamab, pneumonia, PoC, Pocket, post, prioritization, prioritize, proactive, prolonged, pronounced, proud, PRV, PTE, QD, quarantine, question, race, RAD, radio, RECIST, recurrent, reimposition, remdesivir, remote, remotely, reopened, reopening, repair, respiratory, resurgence, retaliation, retifanlimab, Revolutionizing, rituximab, Rodino, RUXCOVID, SCAC, sex, sexual, Shield, shutdown, slower, SMDP, SoC, Society, sought, SPC, standalone, stay, storm, strain, strong, suboptimal, suspected, sweat, sweeping, swollen, symposium, TABRECTA, television, Town, Treasury, trillion, TrOOP, Trump, tuition, uncollectible, underrepresented, underwritten, unpredictable, unusual, utmost, ventilation, veteran, virtual, voluntarily, vomiting, voucher, widespread, worth, Wuhan, XmAb
Removed: acceleration, actuarial, adjusted, affiliated, annum, assured, AtD, Bank, block, Brooke, concept, customary, deducting, deduction, derivative, discontinued, Extensionsand, flare, Israel, mature, minimum, moderate, Norway, partially, persuasive, PIM, placement, possession, proof, redeem, refund, refundable, released, rendered, RESET, Russia, satisfying, scaly, Securing, subside, tackle, transition, trustee, Turkey, Unionand, visit